查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574866

鬱血性心臟衰竭藥物市場規模、佔有率、趨勢分析報告：按藥物、產品、通路、地區、細分市場預測，2024-2030年

Congestive Heart Failure Drugs Market Size, Share & Trends Analysis Report By Drug (ACE Inhibitors, Angiotensin 2 Receptor Blockers), By Product (Injection, Capsule and Tablets), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

鬱血性心臟衰竭藥物市場成長與趨勢：

預計2030年全球鬱血性心臟衰竭藥物市場規模將達198.5億美元，2024年至2030年複合年成長率為14.6%。

鬱血性心臟衰竭（CHF）盛行率的增加、人口老化導致疾病風險增加以及更好的治療方法的研究和開發的增加是推動成長的主要因素。 2020年，全球約有6,434萬人患有心臟衰竭。此外，糖尿病和高血壓等疾病的估計盛行率也很高。

加強研究和開發以獲得更好的治療方法是多種產品出現在管道中的一個主要因素。諾和諾德的 Semaglutide、Zensun 的 Neucardin、拜耳的 vericiguat 和阿斯特捷利康的 AZD4831 都是著名的候選藥物。此外，鈉-葡萄糖共同輸送體2 (SGLT2) 抑制劑治療 CHF 的擴大適應症的核准預計將推動市場成長。例如，2022年2月， Jardiance（Empagliflozin）和2020年5月，Farxiga（Dapagliflozin）作為CHF治療藥物獲得了擴大的適應症。

阿斯特捷利康（AstraZeneca）、百時美施貴寶公司（Bristol-Myers Squibb Company）、安進（Amgen Inc.）和勃林格殷格翰（Boehringer Ingelheim）等主要企業正在新興國家和經濟優勢地區通過併購、監管核准、聯盟和夥伴關係關係策略性地尋求地域擴張。例如，2021年2月，阿斯特捷利康宣佈在中國核准Farxiga（Dapagliflozin）用於患有和不患有第2型糖尿病患者的CHF適應症。在中國之前，該藥已在美國、歐洲和日本核准用於相同適應症。

COVID-19 影響了藥品的供需，使患者難以獲得醫療保健，並減少了大流行期間對產品的需求。隨著法規的實施，研究和開發阻礙了臨床試驗程序。但疫情過後，該產業加快了步伐。

鬱血性心臟衰竭市場報告亮點

  • 2021年，由於高處方率和市場滲透率，ACE抑制劑細分市場佔據最大佔有率。
  • 按藥物類別分類，由於鈉-葡萄糖共同輸送體2 (SGLT2) 抑制劑的推出，預計其他細分市場在預測期內將成長最快。
  • 從分銷管道來看，由於零售藥房與居家醫療環境和處方藥的密切親和性，預計在預測期內將出現良好的成長。
  • 北美鬱血性心臟衰竭市場2023年佔最大佔有率，達37.6%。這是由於主要企業的存在、有利的財政支持以及意識提升。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章鬱血性心臟衰竭藥物市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 鬱血性心臟衰竭藥物市場分析工具
    • 波特的分析
    • PESTEL分析

第4章鬱血性心臟衰竭藥物市場：藥物估計與趨勢分析

  • 細分儀表板
  • 鬱血性心臟衰竭市場：藥物變化分析，百萬美元，2023 年和 2030 年
  • ACE抑制劑
  • 血管收縮素2受體阻斷劑
  • BETA受體阻斷劑
  • 利尿劑
  • 醛固酮拮抗劑
  • 強心藥
  • 其他

第5章鬱血性心臟衰竭藥物市場：產品估算與趨勢分析

  • 細分儀表板
  • 鬱血性心臟衰竭市場：產品變化分析，百萬美元，2023 年和 2030 年
  • 注射
  • 膠囊
  • 藥片

第6章鬱血性心臟衰竭藥物市場：通路估算與趨勢分析

  • 細分儀表板
  • 鬱血性心臟衰竭藥物市場：分銷管道波動分析，百萬美元，2023 年和 2030 年
  • 醫院
  • 零售藥房
  • 網路藥房

第7章鬱血性心臟衰竭藥物市場：區域估計與趨勢分析

  • 2023 年和 2030 年按地區分類的鬱血性心臟衰竭市場佔有率，百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 最新趨勢與影響分析：主要市場參與企業
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Bayer AG
    • Novartis AG
    • Merck & Co., Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Johnson & Johnson Services, Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • Novo Nordisk A/S
簡介目錄
Product Code: GVR-4-68039-987-5

Congestive Heart Failure Drugs Market Growth & Trends:

The global Congestive Heart Failure drugs market size is expected to reach USD 19.85 billion in 2030 and is projected to grow at a CAGR of 14.6% from 2024 to 2030. The increase in the prevalence of congestive heart failure (CHF), the rising aging population leading to increased risk of disease, and growing research and development for better treatment approaches are the key factors augmenting the growth. In 2020, around 64.34 million people worldwide were suffering from heart failure. In addition, its estimated prevalence rate is high in patients with diseases such as diabetes and hypertension.

Increasing research and development for better treatment options is a major factor behind the presence of multiple products in the pipeline. Novo Nordisk's Semaglutide, Zensun's Neucardin, Bayer's vericiguat, and AstraZeneca's AZD4831 are among the prominent drug candidates. Moreover, approval of an extended label for sodium-glucose co-transporter 2 (SGLT2) inhibitors for CHF is expected to fuel market growth. For instance, in February 2022, Jardiance (empagliflozin) and in May 2020, Farxiga (dapagliflozin) received label expansion for the treatment of CHF.

Key players such as AstraZeneca; Bristol-Myers Squibb Company; Amgen Inc.; and Boehringer Ingelheim are strategically engaged in geographical expansions, regulatory approvals, collaborations, and partnerships through mergers and acquisitions in emerging and economically favorable regions. For instance, in February 2021, AstraZeneca announced the approval of Forxiga (dapagliflozin) in China, indicated for CHF with or without type-2 diabetes. Before China, the drug was already approved in the U.S., Europe, and Japan for the same indication.

COVID-19 impacted the demand and supply of drugs, and patients faced difficulty in healthcare access, resulting in a decline in product demand amid the pandemic. Due to imposed restrictions, research and development saw a setback in clinical trial proceedings. However, after the pandemic, the industry regained its pace.

Congestive Heart Failure Drugs Market Report Highlights:

  • In 2021, the ACE inhibitors segment held the largest share due to its high prescription rate and market penetration
  • By drug class, the others segment is expected to be the fastest-growing segment over the forecast period due to the launch of sodium-glucose co-transporter 2 (SGLT2) inhibitors
  • By distribution channel, the retail pharmacies segment is expected to witness lucrative growth over the forecast period due to its high compatibility with home care settings and prescription drugs
  • North America congestive heart failure drugs market held the largest share of 37.6% in 2023. This can be attributed to the presence of key players, favorable funding assistance, and increased patient awareness

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Congestive Heart Failure Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Congestive Heart Failure Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Congestive Heart Failure Drugs Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Congestive Heart Failure Drugs Market: Drug Movement Analysis, USD Million, 2023 & 2030
  • 4.3. ACE Inhibitors
    • 4.3.1. ACE Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Angiotensin 2 Receptor Blockers
    • 4.4.1. Angiotensin 2 Receptor Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Beta Blockers
    • 4.5.1. Beta Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Diuretics
    • 4.6.1. Diuretics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Aldosterone antagonists
    • 4.7.1. Aldosterone antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Inotropes
    • 4.8.1. Inotropes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Congestive Heart Failure Drugs Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Congestive Heart Failure Drugs Market: Product Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Injection
    • 5.3.1. Injection Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Capsule
    • 5.4.1. Capsule Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Tablets
    • 5.5.1. Tablets Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Congestive Heart Failure Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Congestive Heart Failure Drugs Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Congestive Heart Failure Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Congestive Heart Failure Drugs Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Bayer AG
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. AstraZeneca
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Bristol-Myers Squibb Company
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Amgen Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Boehringer Ingelheim International GmbH
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Pfizer, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Johnson & Johnson Services, Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Otsuka Pharmaceutical Co., Ltd.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Eli Lilly and Company
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
    • 8.4.12. Novo Nordisk A/S
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/ Strategic Initiatives